{"id":19542,"date":"2023-12-19T10:46:01","date_gmt":"2023-12-18T23:46:01","guid":{"rendered":"https:\/\/mvec.mcri.edu.au\/?post_type=references&p=19542"},"modified":"2025-06-24T08:19:30","modified_gmt":"2025-06-23T22:19:30","slug":"immunosuppression-in-pregnancy-and-infant-vaccine-recommendations","status":"publish","type":"references","link":"https:\/\/mvec.mcri.edu.au\/vi\/references\/immunosuppression-in-pregnancy-and-infant-vaccine-recommendations\/","title":{"rendered":"Immunosuppression in pregnancy and infant vaccine recommendations"},"content":{"rendered":"
<\/p>\n

L\u00fd l\u1ecbch<\/h2>\n

Immunosuppressive<\/a> therapies play an important role in the treatment of many medical conditions. Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are a specific subset of immunosuppressive medications primarily used for the treatment of inflammatory rheumatic diseases. However, they are increasingly being used to treat many other conditions.<\/span> \u00a0<\/span>Examples of bDMARDs include a<\/span>dalimumab,<\/span> t<\/span>ocilizumab,<\/span> etanercept, infliximab and rituximab<\/a>. <\/span>\u00a0<\/span><\/p>\n

If exposed to vaccine-preventable diseases, individuals with suppressed immune systems may have an increased risk of developing severe disease <\/span>(and of hospitalisation, intensive care admission and death). However, some vaccines (live-attenuated vaccines) may be contraindicated in individuals with immunosuppression due to the potential risk of vaccine-related disease. Additionally, immune response<\/span>S<\/span> to vaccines may be suboptimal. <\/span>\u00a0<\/span><\/p>\n

Immunosuppression <\/span>use <\/span>in pregnancy<\/span> V\u00e0 <\/span>infant <\/span>
<\/div><\/span><\/h2>\n

Due to the broadened scope of use<\/span> c\u1ee7a <\/span>bDMARDs<\/span>, including during pregnancy, there is an increasing number of infants <\/span>exposed to <\/span>bDMARDs<\/span> in utero. The effect that this has on an infant\u2019s immune system is not well understood<\/span>,<\/span> but<\/span> there is<\/span> c\u00e1c<\/span> potential <\/span>v\u00ec <\/span>c\u00f3 \u00fd ngh\u0129a <\/span>implications <\/span>regarding<\/span> the safe use and effectiveness of routine and <\/span>th\u00eam v\u00e0o<\/span> vaccines in infants.<\/span><\/span>\u00a0<\/span><\/p>\n

khuy\u1ebfn ngh\u1ecb<\/span><\/span><\/h3>\n

Specific guidance on the immunisation of infants exposed to immunosuppressive therapy in utero or through breastmilk is outlined in the Australian Immunisation Handbook. Access the guidance \u0111\u00e2y<\/a>.<\/span><\/span><\/p>\n<\/div>

<\/p>\n

T\u00e0i li\u1ec7u<\/h2>\n